Quetiapine and Wolff-Parkinson-White Syndrome
Authors:
Open Access
- 11 December 2020
- journal article
- case report
- Published by Hindawi Limited in Case Reports in Psychiatry
- Vol. 2020, 1-4
Abstract
Quetiapine is occasionally associated with cardiovascular adverse effects such as QTc prolongation. QTc prolongation is a side effect that requires monitoring in order to avoid more serious cardiac complications. One particular understudied area is the potential for antipsychotics to elicit electroconduction abnormalities in patients with Wolff-Parkinson-White (WPW) Syndrome. In the present report, we describe a case of quetiapine overdose in a patient with WPW.Keywords
Funding Information
- Penn State IRB (STUDY00008872)
This publication has 20 references indexed in Scilit:
- Antipsychotics for patients with Wolff-Parkinson-White SyndromeClinical Schizophrenia & Related Psychoses, 2019
- Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)Cochrane Database of Systematic Reviews, 2017
- Sudden Cardiac Death in Pre-Excitation and Wolff-Parkinson-WhiteJACC, 2017
- Risperidone unmasking an accessory pathwayInternational Journal of Cardiology, 2015
- Death due to fulminant neuroleptic malignant syndrome induced by low doses of haloperidol: A rare caseJournal of Forensic and Legal Medicine, 2014
- Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reportsTherapeutic Advances in Psychopharmacology, 2013
- Evaluation and Management of Wolff-Parkinson-White in AthletesSports Health: A Multidisciplinary Approach, 2013
- PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic PatternHeart Rhythm, 2012
- Cardiac Conduction Disturbance Detected in a Pediatric PopulationThe Journal of Pediatrics, 2008
- New Generation Antipsychotic Drugs and QTc Interval ProlongationThe Primary Care Companion For CNS Disorders, 2003